New hope for rare blood cancers: experimental drug ELA026 enters human testing
NCT ID NCT07465835
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-stage study tests an experimental drug called ELA026 in adults with T/NK cell blood cancers that have come back or not responded to prior treatments. The main goals are to check the drug's safety and find the right dose. About 84 participants will be enrolled across multiple centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY T/NK CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30322, United States
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering
RECRUITINGNew York, New York, 10065, United States
-
START, Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.